Literature DB >> 33037768

Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis.

Toon J I De Munck1,2, Pan Xu2, Harm J A Verwijs1, Ad A M Masclee1,2, Daisy Jonkers1,2, Jef Verbeek3, Ger H Koek1,2.   

Abstract

BACKGROUND: The gut-liver axis is considered to play a critical role in the development and progression of nonalcoholic fatty liver disease (NAFLD). The integrity of the epithelial barrier is crucial to protect the liver against the invasion of microbial products from the gut, although its exact role in NAFLD onset and progression is not clear.
METHODS: We performed a systematic review and meta-analysis of studies that addressed the intestinal permeability (IP) in association with NAFLD presence or severity as defined by the presence of nonalcoholic steatohepatitis (NASH) and the degree of steatosis, hepatic inflammation or fibrosis. A total of 14 studies were eligible for inclusion.
RESULTS: Studies investigating IP in adult (n = 6) and paediatric (n = 8) NAFLD showed similar results. Thirteen of the included studies focussed on small IP, two studies on whole gut permeability and none on colonic permeability. In the pooled analysis, NAFLD patients showed an increased small intestinal permeability compared to healthy controls based on dual sugar tests (standardized mean difference 0.79, 95% CI 0.49-1.08) and serum zonulin levels (standardized mean difference 1.04 ng/mL, 95% CI 0.40-1.68). No clear difference in IP was observed between simple steatosis and NASH patients. Furthermore, whole gut and small intestinal permeability increased with the degree of hepatic steatosis in 4/4 studies, while no association with hepatic inflammation or fibrosis was observed.
CONCLUSION: Based on the limited number of studies available, IP appears to be increased in NAFLD patients compared to healthy controls and is associated with the degree of hepatic steatosis.
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd.

Entities:  

Keywords:  gut-liver axis; intestinal barrier; intestinal permeability; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis

Mesh:

Year:  2020        PMID: 33037768      PMCID: PMC7756870          DOI: 10.1111/liv.14696

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   8.754


  40 in total

Review 1.  Regulation of intercellular tight junctions by zonula occludens toxin and its eukaryotic analogue zonulin.

Authors:  A Fasano
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

2.  Large intestine permeability is increased in patients with compensated liver cirrhosis.

Authors:  Kirsten E Pijls; Ger H Koek; Elhaseen E Elamin; Hanne de Vries; Ad A M Masclee; Daisy M A E Jonkers
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-21       Impact factor: 4.052

3.  Multiple gut-liver axis abnormalities in children with obesity with and without hepatic involvement.

Authors:  S Guercio Nuzio; M Di Stasi; L Pierri; J Troisi; M Poeta; A Bisogno; F Belmonte; M Tripodi; D Di Salvio; G Massa; R Savastano; P Cavallo; M Boffardi; D Ziegenhardt; I Bergheim; C Mandato; P Vajro
Journal:  Pediatr Obes       Date:  2016-06-28       Impact factor: 4.000

Review 4.  Risk factors associated with intestinal permeability in an adult population: A systematic review.

Authors:  Bradley Leech; Erica McIntyre; Amie Steel; David Sibbritt
Journal:  Int J Clin Pract       Date:  2019-07-05       Impact factor: 2.503

5.  Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity.

Authors:  Valentina Giorgio; Luca Miele; Luigi Principessa; Francesca Ferretti; Maria Pia Villa; Valentina Negro; Antonio Grieco; Anna Alisi; Valerio Nobili
Journal:  Dig Liver Dis       Date:  2014-03-12       Impact factor: 4.088

Review 6.  The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease.

Authors:  Tim Vanuytsel; Séverine Vermeire; Isabelle Cleynen
Journal:  Tissue Barriers       Date:  2013-12-10

Review 7.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

8.  Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis.

Authors:  Ashkan Farhadi; Sushama Gundlapalli; Maliha Shaikh; Constantine Frantzides; Laura Harrell; Mary M Kwasny; Ali Keshavarzian
Journal:  Liver Int       Date:  2008-04-07       Impact factor: 5.828

9.  Higher Levels of Serum Zonulin May Rather Be Associated with Increased Risk of Obesity and Hyperlipidemia, Than with Gastrointestinal Symptoms or Disease Manifestations.

Authors:  Bodil Ohlsson; Marju Orho-Melander; Peter M Nilsson
Journal:  Int J Mol Sci       Date:  2017-03-08       Impact factor: 5.923

Review 10.  Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Toon J I De Munck; Pan Xu; Harm J A Verwijs; Ad A M Masclee; Daisy Jonkers; Jef Verbeek; Ger H Koek
Journal:  Liver Int       Date:  2020-10-21       Impact factor: 8.754

View more
  17 in total

Review 1.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

2.  The Human Milk Oligosaccharide 2'-Fucosyllactose Alleviates Liver Steatosis, ER Stress and Insulin Resistance by Reducing Hepatic Diacylglycerols and Improved Gut Permeability in Obese Ldlr-/-.Leiden Mice.

Authors:  Eveline Gart; Kanita Salic; Martine C Morrison; Martin Giera; Joline Attema; Christa de Ruiter; Martien Caspers; Frank Schuren; Ivana Bobeldijk-Pastorova; Marianne Heer; Yan Qin; Robert Kleemann
Journal:  Front Nutr       Date:  2022-06-17

3.  Individuals with Metabolic Syndrome Show Altered Fecal Lipidomic Profiles with No Signs of Intestinal Inflammation or Increased Intestinal Permeability.

Authors:  Mia J Coleman; Luis M Espino; Hernan Lebensohn; Marija V Zimkute; Negar Yaghooti; Christina L Ling; Jessica M Gross; Natalia Listwan; Sandra Cano; Vanessa Garcia; Debbie M Lovato; Susan L Tigert; Drew R Jones; Rama R Gullapalli; Neal E Rakov; Euriko G Torrazza Perez; Eliseo F Castillo
Journal:  Metabolites       Date:  2022-05-11

Review 4.  Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases.

Authors:  Winston Hernández-Ceballos; Jacqueline Cordova-Gallardo; Nahum Mendez-Sanchez
Journal:  J Clin Transl Hepatol       Date:  2021-03-08

Review 5.  Role and Mechanism of Gut Microbiota in Human Disease.

Authors:  Yinwei Chen; Jinghua Zhou; Li Wang
Journal:  Front Cell Infect Microbiol       Date:  2021-03-17       Impact factor: 5.293

Review 6.  Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis.

Authors:  Toon J I De Munck; Pan Xu; Harm J A Verwijs; Ad A M Masclee; Daisy Jonkers; Jef Verbeek; Ger H Koek
Journal:  Liver Int       Date:  2020-10-21       Impact factor: 8.754

7.  Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury.

Authors:  Estefanía Caballano-Infantes; Alberto García-García; Carlos Lopez-Gomez; Alejandro Cueto; Mercedes Robles-Diaz; Aida Ortega-Alonso; Flores Martín-Reyes; Ismael Alvarez-Alvarez; Isabel Arranz-Salas; Francisco Ruiz-Cabello; Isabel M Lucena; Eduardo García-Fuentes; Raúl J Andrade; Miren García-Cortes
Journal:  Biomedicines       Date:  2021-12-28

Review 8.  The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease.

Authors:  Roberta Forlano; Benjamin H Mullish; Lauren A Roberts; Mark R Thursz; Pinelopi Manousou
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

Review 9.  The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.

Authors:  Qian Song; Xiang Zhang
Journal:  Biomedicines       Date:  2022-02-23

10.  Inhibition of cyclooxygenase-2 enhanced intestinal epithelial homeostasis via suppressing β-catenin signalling pathway in experimental liver fibrosis.

Authors:  Linhao Zhang; Yang Tai; Chong Zhao; Xiao Ma; Shihang Tang; Huan Tong; Chengwei Tang; Jinhang Gao
Journal:  J Cell Mol Med       Date:  2021-06-19       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.